Short answer: For most service members, no. The Defense Health Agency's September 17, 2026 clinical practice guideline says neither a diagnosis of testosterone deficiency nor stable maintenance therapy is, of itself, a basis for a duty limitation or a change in deployment status.
The details
The guideline says a member who is stable on therapy should be deployable without a waiver, depending on the formulation. It also asks the prescriber to confirm a supply that covers the deployment before departure.
The exception
For aeromedical, dive, submarine, and nuclear duty, both the diagnosis and the therapy may bear on qualification. Those decisions belong to the service authority under its own instruction, and the guideline does not change those requirements. If you are in one of those communities, start with your flight surgeon or medical officer.
Who this applies to
The guideline is written for care delivered inside military medicine. It also says that declining evaluation or treatment carries no adverse personnel consequence. A prescription from a private clinic is a different path, so ask your command how it wants that documented.
More: TRT and Special Duty and Deploying on Testosterone.
Talk to us
Hew Health is a private, cash-pay practice in Destin and Orlando, Florida, with telemedicine in 47 states. We are not TRICARE and not part of military medicine. Request a consultation at hewhealth.com or call (850) 820-8850. Discounted pricing is available for military, law enforcement, and first responders.
Hew Health is a private medical practice and is not affiliated with the Department of Defense, TRICARE, or any branch of the U.S. Armed Forces. General information as of November 8, 2026, not medical advice. Testosterone is a Schedule III controlled substance.